Thousand Oaks biotech Amgen announced two collaborations Dec. 11 aimed at improving outcomes for osteoporosis and migraine patients and developing treatments for inflammatory diseases, among other goals. Amgen partnered with Magellan Health’s pharmacy benefit management subsidiary, Magellan Rx Management, to identify gaps in treatment for osteoporosis patients who have suffered a bone fracture and migraine…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
